ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management

Xianxiong Ma; Jiancheng Cheng; Peng Zhao; Lei Li; Kaixiong Tao; Hengyu Chen
Journal of Cellular and Molecular Medicine2020DOI: 10.1111/jcmm.15393
20阅读
引用收藏
分享

摘要

Increasing evidence suggested DNA methylation may serve as potential prognostic biomarkers; however, few related DNA methylation signatures have been established for prediction of lung cancer prognosis. We aimed at developing DNA methylation signature to improve prognosis prediction of stage I lung adenocarcinoma (LUAD). A total of 268 stage I LUAD patients from the Cancer Genome Atlas (TCGA) database were included. These patients were separated into training and internal validation datasets. GSE39279 was used as an external validation set. A 13‐DNA methylation signature was identified to be crucially relevant to the relapse‐free survival (RFS) of patients with stage I LUAD by the univariate Cox proportional hazard analysis and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis and multivariate Cox proportional hazard analysis in the training dataset. The Kaplan‐Meier analysis indicated that the 13‐DNA methylation signature could significantly distinguish the high‐ and low‐risk patients in entire TCGA dataset, internal validation and external validation datasets. The receiver operating characteristic (ROC) analysis further verified that the 13‐DNA methylation signature had a better value to predict the RFS of stage I LUAD patients in internal validation, external validation and entire TCGA datasets. In addition, a nomogram combining methylomic risk scores with other clinicopathological factors was performed and the result suggested the good predictive value of the nomogram. In conclusion, we successfully built a DNA methylation‐associated nomogram, enabling prediction of the RFS of patients with stage I LUAD.

学科与关键词

关键词
DNA methylationLUADNomogramRecurrence‐free survivalSignature
相关
加载中…
  • DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
    Xu, Feng; He, Lulu; Zhan, Xueqin; Chen, Jiexin; Xu, Huan; Huang, Xiaoling; Li, Yangyi; Zheng, Xiaohe; Lin, Ling*; Chen, Yongsong*Aging-US, 2020, 12(24): 25275-25293.被引 3
  • Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
    Yang, Xin; Wen, Xiaofeng; Guo, Qin; Zhang, Yunfeng; Liang, Zhenxing; Wu, Qian; Li, Zhihao; Ruan, Weimei; Ye, Zhujia; Wang, Hong; Chen, Zhiwei; Fan, Jian-Bing; Lan, Ping*; Liu, Huashan*; Wu, Xianrui*Clinical Epigenetics, 2022, 14(1): 160.被引 3
  • Identification and Validation of Three-Gene Signature in Lung Squamous Cell Carcinoma by Integrated Transcriptome and Methylation Analysis
    Li, Guanghua; Wu, Libo; Yu, Jiaxing; Zhai, Siyang; Deng, Hailong; Wang, Qiushi*Journal of Oncology, 2022, 2022: 9688040.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cellular and Molecular Medicine
发表日期
2020
卷期
第 24 卷, 第 13 期
页码
7576-7589
DOI
10.1111/jcmm.15393
成果收录
CHINAJOURNAL

作者

  • X

    Xianxiong Ma (第一作者)

  • J

    Jiancheng Cheng

查看全部 6 位作者收起作者
  • P

    Peng Zhao

  • L

    Lei Li

  • K

    Kaixiong Tao

  • H

    Hengyu Chen

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417